Proteinase- activated receptors 1 and 2 and the regulation of porcine coronary artery contractility: a role for distinct tyrosine kinase pathways

被引:12
作者
El-Daly, Mahmoud [1 ,2 ,3 ]
Saifeddine, Mahmoud [1 ,2 ,3 ]
Mihara, Koichiro [1 ,2 ,3 ]
Ramachandran, Rithwik [1 ,2 ,3 ]
Triggle, Christopher R. [1 ,2 ,3 ,4 ,5 ]
Hollenberg, Morley D. [1 ,2 ,3 ,6 ]
机构
[1] Libin Cardiovasc Inst Alberta, Calgary, AB, Canada
[2] Snyder Inst Chron Dis, Calgary, AB, Canada
[3] Univ Calgary, Fac Med, Dept Physiol & Pharmacol, Calgary, AB T2N 4N1, Canada
[4] Weill Cornell Med Coll Qatar, Dept Pharmacol, Doha, Qatar
[5] Weill Cornell Med Coll Qatar, Dept Med Educ, Doha, Qatar
[6] Univ Calgary, Fac Med, Dept Med, Calgary, AB T2N 4N1, Canada
基金
加拿大健康研究院;
关键词
angiotensin-II; coronary contraction; cyclooxygenase; EGF; MAPKinase; PGF(2); PARs; protease; proteinase-activated receptors; tyrosine kinase signalling pathways; SIGNAL-TRANSDUCTION PATHWAYS; ENDOTHELIUM-DEPENDENT RELAXATION; PROSTAGLANDIN E-2 FORMATION; GASTRIC SMOOTH-MUSCLE; GROWTH-FACTOR; EGF RECEPTOR; COUPLED RECEPTORS; ANGIOTENSIN-II; NEUTROPHIL ELASTASE; THROMBIN RECEPTOR;
D O I
10.1111/bph.12593
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and PurposeBecause angiotensin-II-mediated porcine coronary artery (PCA) vasoconstriction is blocked by protein tyrosine kinase (PYK) inhibitors, we hypothesized that proteinase-activated receptors (PARs), known to regulate vascular tension, like angiotensin-II, would also cause PCA contractions via PYK-dependent signalling pathways. Experimental ApproachContractions of intact and endothelium-free isolated PCA rings, stimulated by PAR(1)/PAR(2)-activating peptides, angiotensin-II, PGF(2), EGF, PDGF and KCl, were monitored with/without multiple signalling pathway inhibitors, including AG-tyrphostins AG18 (non-specific PYKs), AG1478 (EGF-receptor kinase), AG1296 (PDGF receptor kinase), PP1 (Src kinase), U0126 and PD98059 (MEK/MAPKinase kinase), indomethacin/SC-560/NS-398 (COX-1/2) and L-NAME (NOS). Key ResultsAG18 inhibited the contractions induced by all the agonists except KCl, whereas U0126 attenuated contractions induced by PAR(1)/PAR(2) agonists, EGF and angiotensin-II, but not by PGF(2), the COX-produced metabolites of arachidonate and KCl. PP1 only affected the responses to PAR(1)/PAR(2)-activating peptides and angiotensin-II. The EGF-kinase inhibitor, AG1478, attenuated contractions initiated by the PARs (PAR(2) >> PAR(1)) and EGF itself, but not by angiotensin-II, PGF(2) or KCl. COX-1/2 inhibitors blocked the contractions induced by all the agonists, except KCl and PGF(2). Conclusion and ImplicationsPAR(1/2)-mediated contractions of the PCA are dependent on Src and MAPKinase and, in part, involve EGF-receptor-kinase transactivation and the generation of a COX-derived contractile agonist. However, the PYK signalling pathways used by PARs are distinct from each other and from those triggered by angiotensin-II and EGF. These signalling pathways may be therapeutic targets for managing coagulation-proteinase-induced coronary vasospasm.
引用
收藏
页码:2413 / 2425
页数:13
相关论文
共 53 条
  • [1] Structure, function and pathophysiology of protease activated receptors
    Adams, Mark N.
    Ramachandran, Rithwik
    Yau, Mei-Kwan
    Suen, Jacky Y.
    Fairlie, David P.
    Hollenberg, Morley D.
    Hooper, John D.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2011, 130 (03) : 248 - 282
  • [2] Proteinase-activated receptor 2: Differential activation of the receptor by tethered ligand and soluble peptide analogs
    Al-Ani, B
    Wijesuriya, SJ
    Hollenberg, MD
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (03) : 1046 - 1054
  • [3] THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: CATALYTIC RECEPTORS
    Alexander, Stephen P. H.
    Benson, Helen E.
    Faccenda, Elena
    Pawson, Adam J.
    Sharman, Joanna L.
    Spedding, Michael
    Peters, John A.
    Harmar, Anthony J.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2013, 170 (08) : 1676 - 1705
  • [4] THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: G PROTEIN-COUPLED RECEPTORS
    Alexander, Stephen P. H.
    Benson, Helen E.
    Faccenda, Elena
    Pawson, Adam J.
    Sharman, Joanna L.
    Spedding, Michael
    Peters, John A.
    Harmar, Anthony J.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2013, 170 (08) : 1459 - 1581
  • [5] Intrathecal administration of proteinase-activated receptor-2 agonists produces hyperalgesia by exciting the cell bodies of primary sensory neurons
    Alier, Kwai A.
    Endicott, Jaclyn A.
    Stemkowski, Patrick L.
    Cenac, Nicolas
    Cellars, Laurie
    Chapman, Kevin
    Andrade-Gordon, Patricia
    Vergnolle, Nathalie
    Smith, Peter A.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 324 (01) : 224 - 233
  • [6] The selectivity of protein kinase inhibitors: a further update
    Bain, Jenny
    Plater, Lorna
    Elliott, Matt
    Shpiro, Natalia
    Hastie, C. James
    Mclauchlan, Hilary
    Klevernic, Iva
    Arthur, J. Simon C.
    Alessi, Dario R.
    Cohen, Philip
    [J]. BIOCHEMICAL JOURNAL, 2007, 408 : 297 - 315
  • [7] Agonists and antagonists of protease activated receptors (PARs)
    Barry, GD
    Le, GT
    Fairlie, DP
    [J]. CURRENT MEDICINAL CHEMISTRY, 2006, 13 (03) : 243 - 265
  • [8] Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation
    Caruso, Roberta
    Pallone, Francesco
    Fina, Daniele
    Gioia, Valentina
    Peluso, Ilaria
    Caprioli, Flavio
    Stolfi, Carmine
    Perfetti, Alessandra
    Spagnoli, Luigi Giusto
    Palmieri, Giampiero
    MacDonald, Thomas T.
    Monteleone, Giovanni
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2006, 169 (01) : 268 - 278
  • [9] Guidelines for the effective use of chemical inhibitors of protein function to understand their roles in cell regulation
    Cohen, Philip
    [J]. BIOCHEMICAL JOURNAL, 2010, 425 : 53 - 54
  • [10] Thrombin signalling and protease-activated receptors
    Coughlin, SR
    [J]. NATURE, 2000, 407 (6801) : 258 - 264